NASDAQ:IPXL - Impax Laboratories Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$18.30 As of 05/4/2018 01:00 AM ET

+0.30 (1.20%)

Get New Impax Laboratories Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for IPXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPXL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Impax Laboratories in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.30.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in Impax Laboratories. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/22/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/21/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/19/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/17/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/16/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/15/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/1/2018	Barclays	Initiated Coverage	Overweight ➝ Overweight	$27.00	High	i
4/16/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$18.00 ➝ $20.00	High	i
3/7/2018	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$24.00	High	i
3/2/2018	Royal Bank of Canada	Set Price Target	Hold	$20.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
3/1/2018	Cowen	Set Price Target	Hold	$21.00	Medium	i Rating by Ken Cacciatore at Cowen Inc
3/1/2018	Canaccord Genuity	Set Price Target	Hold	$19.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
3/1/2018	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Louise Chen at Cantor Fitzgerald
2/22/2018	Canaccord Genuity	Set Price Target	Hold	$19.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
1/2/2018	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$22.00	Medium	i Rating by A. Fadia at SVB Leerink LLC
12/18/2017	Canaccord Genuity	Set Price Target	Hold	$19.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
12/15/2017	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Louise Chen at Cantor Fitzgerald
12/12/2017	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$18.00	High	i
11/10/2017	Cowen	Reiterated Rating	Hold	$16.00	N/A	i Rating by Tyler Van Buren at Cowen Inc
11/10/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$25.00 ➝ $35.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
10/30/2017	UBS Group	Boost Price Target	Sell	$12.00 ➝ $16.00	N/A	i
10/17/2017	Royal Bank of Canada	Set Price Target	Hold	$17.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
10/17/2017	Canaccord Genuity	Set Price Target	Hold	$19.00	N/A	i Rating by Dewey Steadman at Canaccord Genuity
10/17/2017	Cantor Fitzgerald	Set Price Target	Buy	$25.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Neutral	$20.00	High	i
9/25/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$25.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/23/2017	BTIG Research	Reiterated Rating	Buy	$20.00 ➝ $27.00	Low	i
9/19/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$23.00	Low	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
9/19/2017	Citigroup	Boost Price Target	Buy	$23.00	Low	i
9/17/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$17.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
9/11/2017	Cantor Fitzgerald	Boost Price Target	Overweight	$20.00 ➝ $25.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
9/6/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$20.00 ➝ $25.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
8/10/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00 ➝ $17.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
8/10/2017	Piper Jaffray Companies	Set Price Target	Hold	$17.00	High	i Rating by David Amsellem at Piper Jaffray Companies
8/9/2017	Canaccord Genuity	Set Price Target	Hold	$19.00	High	i Rating by Dewey Steadman at Canaccord Genuity
8/9/2017	Cowen	Set Price Target	Hold	$12.00 ➝ $20.00	High	i Rating by Tyler Van Buren at Cowen Inc
8/9/2017	Cantor Fitzgerald	Set Price Target	Buy	$20.00	High	i Rating by Louise Chen at Cantor Fitzgerald
7/31/2017	Canaccord Genuity	Initiated Coverage	Hold ➝ Hold	$19.00	High	i Rating by Dewey Steadman at Canaccord Genuity
7/18/2017	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$9.00 ➝ $16.00	Low	i
7/17/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$20.00 ➝ $21.00	Low	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
6/23/2017	BMO Capital Markets	Reiterated Rating	Hold	$16.00	Low	i
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$20.00	Low	i
6/13/2017	Royal Bank of Canada	Reiterated Rating	Hold	$15.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
6/12/2017	Janney Montgomery Scott	Reiterated Rating	Neutral	$21.00	High	i
5/11/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$10.00 ➝ $62.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
4/11/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform		Low	i Rating by Randall Stanicky at Royal Bank of Canada
4/8/2017	Royal Bank of Canada	Set Price Target	Hold	$10.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
4/5/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$11.00 ➝ $15.00	High	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
4/2/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$10.00	Low	i
3/27/2017	Guggenheim	Reiterated Rating	Buy	$20.00	Low	i
3/8/2017	Susquehanna Bancshares	Downgrade	Positive ➝ Neutral	$18.00 ➝ $10.00	Low	i
3/8/2017	UBS Group	Downgrade	Positive ➝ Neutral		N/A	i Rating by Marc Goodman at UBS Group AG
3/8/2017	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$11.00	Low	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
3/2/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$15.00 ➝ $10.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
3/1/2017	Piper Jaffray Companies	Downgrade	Neutral ➝ Underweight	$7.00	N/A	i
1/17/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform		N/A	i Rating by Randall Stanicky at Royal Bank of Canada
1/13/2017	BMO Capital Markets	Reiterated Rating	Sell ➝ Market Perform	$18.00	N/A	i
1/3/2017	Royal Bank of Canada	Reiterated Rating	Hold	$15.00	N/A	i
12/28/2016	Janney Montgomery Scott	Initiated Coverage	init ➝ Neutral	$15.00	N/A	i
12/23/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$17.00	N/A	i
11/14/2016	WallachBeth Capital	Downgrade	Buy ➝ Hold	$30.00 ➝ $18.00	N/A	i
11/11/2016	UBS Group	Set Price Target	Sell	$12.00	N/A	i Rating by Marc Goodman at UBS Group AG
11/10/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$30.00 ➝ $18.00	N/A	i
11/10/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$30.00 ➝ $18.00	N/A	i
11/7/2016	Bank of America	Downgrade	Neutral ➝ Underperform	$19.00	N/A	i
9/27/2016	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$25.00 ➝ $26.00	N/A	i Rating by Gary Nachman at The Goldman Sachs Group, Inc.
8/15/2016	Northland Securities	Upgrade	Market Perform ➝ Outperform	$30.00	N/A	i
8/13/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$40.00 ➝ $32.00	N/A	i
8/11/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$35.00 ➝ $30.00	N/A	i
8/10/2016	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold	$31.00 ➝ $24.00	N/A	i
8/10/2016	SVB Leerink	Lower Price Target	Market Perform	$33.00 ➝ $24.00	N/A	i
8/10/2016	WallachBeth Capital	Lower Price Target	Buy	$40.00 ➝ $30.00	N/A	i
8/10/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$35.00 ➝ $30.00	N/A	i
7/6/2016	SVB Leerink	Reiterated Rating	Market Perform	$31.00 ➝ $33.00	N/A	i Rating by Jason Gerberry at SVB Leerink LLC
6/28/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$30.00	N/A	i
6/22/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$41.00 ➝ $40.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
6/22/2016	UBS Group	Reiterated Rating	Sell	$28.00	N/A	i Rating by Marc Goodman at UBS Group AG
6/22/2016	SVB Leerink	Reiterated Rating	Market Perform	$31.00	N/A	i Rating by Jason Gerberry at SVB Leerink LLC
6/22/2016	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold	$42.00 ➝ $31.00	N/A	i
6/21/2016	Bank of America	Upgrade	Underperform ➝ Neutral		N/A	i

(Data available from 6/14/2016 forward)

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Today's Range

Now: $18.30

$17.40

$18.95

50 Day Range

MA: $18.30

$18.30

52 Week Range

Now: $18.30

$13.05

$25.70

Volume

3,041,017 shs

Average Volume

945,265 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Impax Laboratories?

The following Wall Street sell-side analysts have issued reports on Impax Laboratories in the last twelve months:
View the latest analyst ratings for IPXL.

What is the current price target for Impax Laboratories?

0 Wall Street analysts have set twelve-month price targets for Impax Laboratories in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Impax Laboratories in the next year.
View the latest price targets for IPXL.

What is the current consensus analyst rating for Impax Laboratories?

Impax Laboratories currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IPXL.

What other companies compete with Impax Laboratories?

Other companies that are similar to Impax Laboratories include Johnson & Johnson, Pfizer, Eli Lilly and, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics and Supernus Pharmaceuticals.

How do I contact Impax Laboratories' investor relations team?

Impax Laboratories' physical mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company's listed phone number is (908) 947-3120 and its investor relations email address is [email protected] The official website for Impax Laboratories is www.impaxlabs.com.